Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and ... EON: Enhanced Online News (press release) “Emergent is pleased with the progress of our Phase 1b study of TRU-016 in combination with rituximab in front line patients with CLL. The strong enrollment and the encouraging early data from this open label study are expected to facilitate an ... |
